Purchasability


Ligand source activities (1 row/activity)

Select all ChEMBL ID Receptor Species Purchasable p-value
(-log)		 Activity
Type		 Activity
Relation		 Activity
Value		 Unit Assay Type Assay Description Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles
CHEMBL3786631 cxcr3_human Human No 6.0 EC50 = 1071.5 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786631 cxcr3_human Human No 6.0 EC50 = 1071.5 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786480 cxcr3_human Human No 7.0 EC50 = 112.2 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786480 cxcr3_human Human No 7.0 EC50 = 112.2 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787121 cxcr3_human Human No 5.9 EC50 = 1230.3 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
823 19 3 8 5.7 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)S(=O)(=O)C)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787121 cxcr3_human Human No 5.9 EC50 = 1230.3 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
823 19 3 8 5.7 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)S(=O)(=O)C)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3785515 cxcr3_human Human No 5.9 EC50 = 1318.3 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3785515 cxcr3_human Human No 5.9 EC50 = 1318.3 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786480 cxcr3_human Human No 6.9 EC50 = 138.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786480 cxcr3_human Human No 6.9 EC50 = 138.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786152 cxcr3_human Human No 6.8 EC50 = 144.5 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
759 19 3 6 6.8 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786152 cxcr3_human Human No 6.8 EC50 = 144.5 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
759 19 3 6 6.8 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786864 cxcr3_human Human No 6.8 EC50 = 166.0 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
683 17 3 6 4.8 CC(=O)CCC(=O)N1CC2=CC=CC=C2CC1C(=O)NCCCCC(C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OC(C)(C)C
CHEMBL3786152 cxcr3_human Human No 6.8 EC50 = 166.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
759 19 3 6 6.8 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786864 cxcr3_human Human No 6.8 EC50 = 166.0 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
683 17 3 6 4.8 CC(=O)CCC(=O)N1CC2=CC=CC=C2CC1C(=O)NCCCCC(C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OC(C)(C)C
CHEMBL3786152 cxcr3_human Human No 6.8 EC50 = 166.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
759 19 3 6 6.8 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787609 cxcr3_human Human No 6.7 EC50 = 195.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787404 cxcr3_human Human No 6.7 EC50 = 195.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3787609 cxcr3_human Human No 6.7 EC50 = 195.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787404 cxcr3_human Human No 6.7 EC50 = 195.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3787404 cxcr3_human Human No 5.7 EC50 = 2187.8 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3787404 cxcr3_human Human No 5.7 EC50 = 2187.8 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3786144 cxcr3_human Human No 6.6 EC50 = 229.1 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786864 cxcr3_human Human No 6.6 EC50 = 229.1 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
683 17 3 6 4.8 CC(=O)CCC(=O)N1CC2=CC=CC=C2CC1C(=O)NCCCCC(C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OC(C)(C)C
CHEMBL3786144 cxcr3_human Human No 6.6 EC50 = 229.1 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786864 cxcr3_human Human No 6.6 EC50 = 229.1 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
683 17 3 6 4.8 CC(=O)CCC(=O)N1CC2=CC=CC=C2CC1C(=O)NCCCCC(C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OC(C)(C)C
CHEMBL3786631 cxcr3_human Human No 6.6 EC50 = 234.4 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786631 cxcr3_human Human No 6.6 EC50 = 234.4 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786144 cxcr3_human Human No 6.6 EC50 = 263.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786144 cxcr3_human Human No 6.6 EC50 = 263.0 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787404 cxcr3_human Human No 6.5 EC50 = 316.2 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3787404 cxcr3_human Human No 6.5 EC50 = 316.2 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
585 14 4 5 5.3 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1)C(=O)NCC(C3=CC=CC=C3)C4=CC=CC=C4
CHEMBL3786459 cxcr3_human Human No 7.3 EC50 = 50.1 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
805 20 3 8 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC(=C(C=C3)OC)OC)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786459 cxcr3_human Human No 7.3 EC50 = 50.1 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
805 20 3 8 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC(=C(C=C3)OC)OC)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786522 cxcr3_human Human No 6.3 EC50 = 512.9 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
763 18 3 7 6.5 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)F)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786522 cxcr3_human Human No 6.3 EC50 = 512.9 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
763 18 3 7 6.5 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)F)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786631 cxcr3_human Human No 7.2 EC50 = 58.9 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786631 cxcr3_human Human No 7.2 EC50 = 58.9 Funct
Positive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink2-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
745 18 3 6 6.4 CC(C)(C)OC(=O)NCCCCC(C(=O)NCC(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)C3CC4=CC=CC=C4CN3C(=O)CCC(=O)C5=CC=CC=C5
CHEMBL3786577 cxcr3_human Human No 5.2 EC50 = 6025.6 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
775 19 3 7 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)OC)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3786577 cxcr3_human Human No 5.2 EC50 = 6025.6 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
775 19 3 7 6.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC(=O)C3=CC=C(C=C3)OC)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787609 cxcr3_human Human No 7.2 EC50 = 61.7 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787609 cxcr3_human Human No 7.2 EC50 = 61.7 Funct
Positive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader methodPositive allosteric modulation of ProLink1-tagged wild type CXCR3 (unknown origin) expressed in HEK293T cells assessed as beta-arrestin-2 recruitment incubated for 4 hrs by chemiluminescence-based microplate reader method
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL2181467 cxcr3_human Human No 6.2 EC50 = 631.0 Funct
Agonist activity at CXCR3 expressed in HEK293 cells by [35S]GTPgamma binding assayAgonist activity at CXCR3 expressed in HEK293 cells by [35S]GTPgamma binding assay
645 15 3 5 4.8 C1C(N(CC2=CC=CC=C21)C(=O)CCC(=O)C3=CC=CC=C3)C(=O)NC(CCCCN)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3785564 cxcr3_human Human No 5.1 EC50 = 8511.4 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
731 18 3 5 7.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787609 cxcr3_human Human No 5.1 EC50 = 8511.4 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3785564 cxcr3_human Human No 5.1 EC50 = 8511.4 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
731 18 3 5 7.4 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL3787609 cxcr3_human Human No 5.1 EC50 = 8511.4 Funct
Positive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assayPositive allosteric modulation of human CXCR3 expressed in HEK293T cell membranes after 30 mins by [35S]GTPgammaS incorporation assay
717 17 3 5 7.1 CC(C)(C)OC(=O)NC(CCCCNC(=O)C1CC2=CC=CC=C2CN1C(=O)CCC3=CC=CC=C3)C(=O)NCC(C4=CC=CC=C4)C5=CC=CC=C5
CHEMBL1681882 cxcr3_human Human No 9.7 IC50 = 0.2 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL1681882 cxcr3_human Human No 9.7 IC50 = 0.2 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL1681882 cxcr3_human Human No 9.7 IC50 = 0.2 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL1921866 cxcr3_human Human No 9.5 IC50 = 0.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
551 8 3 8 4.2 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCC(C)O)N
CHEMBL1921863 cxcr3_human Human No 9.5 IC50 = 0.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
506 6 2 7 4.5 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NC)N
CHEMBL3116468 cxcr3_human Human No 9.5 IC50 = 0.3 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
517 6 1 6 5.3 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C5=NC=CN5)Cl
CHEMBL1921866 cxcr3_human Human No 9.5 IC50 = 0.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
551 8 3 8 4.2 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCC(C)O)N
CHEMBL1921863 cxcr3_human Human No 9.5 IC50 = 0.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
506 6 2 7 4.5 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NC)N
CHEMBL1077831 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to IP10 in bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to IP10 in buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1921865 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
537 8 3 8 3.8 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCO)N
CHEMBL256589 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
632 12 0 9 5.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=CC=C4
CHEMBL1077831 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to IP10 in bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to IP10 in buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3116476 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
531 6 1 9 4.3 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C5=NN=C(O5)C)N
CHEMBL1921865 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
537 8 3 8 3.8 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCO)N
CHEMBL256589 cxcr3_human Human No 9.4 IC50 = 0.4 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
632 12 0 9 5.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=CC=C4
CHEMBL1077831 cxcr3_human Human No 9.2 IC50 = 0.6 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to MIG in bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to MIG in buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 9.2 IC50 = 0.6 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to MIG in bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to MIG in buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL403036 cxcr3_human Human No 9.2 IC50 = 0.7 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL403036 cxcr3_human Human No 9.2 IC50 = 0.7 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL403036 cxcr3_human Human No 9.2 IC50 = 0.7 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL403036 cxcr3_human Human No 9.2 IC50 = 0.7 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in RPMI bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in RPMI buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1921864 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
574 7 2 10 5.6 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCC(F)(F)F)N
CHEMBL1921858 cxcr3_human Human Yes 9.1 IC50 = 0.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
492 6 2 7 4.1 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N
CHEMBL254083 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
598 9 0 9 5.6 CCS(=O)(=O)CCN(C(C)C1=NC2=CC=CC=C2C=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in RPMI bufferAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in RPMI buffer
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1921858 cxcr3_human Human Yes 9.1 IC50 = 0.8 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
492 6 2 7 4.1 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N
CHEMBL3116487 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
575 7 2 11 4.0 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C5=NN=C(O5)NCC
CHEMBL1921864 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
574 7 2 10 5.6 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCC(F)(F)F)N
CHEMBL1921858 cxcr3_human Human Yes 9.1 IC50 = 0.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
492 6 2 7 4.1 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N
CHEMBL254083 cxcr3_human Human No 9.1 IC50 = 0.8 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
598 9 0 9 5.6 CCS(=O)(=O)CCN(C(C)C1=NC2=CC=CC=C2C=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1921879 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
550 6 2 8 4.2 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC(C)C
CHEMBL1921868 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
668 10 3 13 4.8 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCNS(=O)(=O)C(F)(F)F)N
CHEMBL576097 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)F)C(F)(F)F
CHEMBL578192 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL570665 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL578187 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1921879 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
550 6 2 8 4.2 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC(C)C
CHEMBL1921868 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
668 10 3 13 4.8 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCNS(=O)(=O)C(F)(F)F)N
CHEMBL576097 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)F)C(F)(F)F
CHEMBL578192 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL570665 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL578187 cxcr3_human Human No 9.1 IC50 = 0.9 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1077831 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077828 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
640 9 0 10 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCN(CC4)C(C)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1077830 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
635 11 0 11 4.3 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-ITAC from human CXCR3 expressed in human PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-ITAC from human CXCR3 expressed in human PBMC after 2 hrs in RPMI buffer by scintillation counting
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL404201 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
605 9 0 9 5.7 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL3116486 cxcr3_human Human No 9.0 IC50 = 1 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
591 7 3 12 3.6 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC(=C(N=C4Cl)C5=NN=C(O5)NCC)N
CHEMBL1077831 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077828 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
640 9 0 10 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCN(CC4)C(C)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1077830 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
635 11 0 11 4.3 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]-ITAC from human CXCR3 expressed in human PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-ITAC from human CXCR3 expressed in human PBMC after 2 hrs in RPMI buffer by scintillation counting
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL404201 cxcr3_human Human No 9.0 IC50 = 1 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
605 9 0 9 5.7 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1681882 cxcr3_mouse Mouse No 9.0 IC50 = 1.1 Funct
Antagonist activity at mouse CXCR3Antagonist activity at mouse CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL1921891 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
511 6 1 6 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL576096 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)OC(F)(F)F
CHEMBL576099 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=CC=C6)OC(F)(F)F
CHEMBL578189 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1681882 cxcr3_mouse Mouse No 9.0 IC50 = 1.1 Funct
Antagonist activity at mouse CXCR3Antagonist activity at mouse CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL1921891 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
511 6 1 6 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL576096 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)OC(F)(F)F
CHEMBL576099 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=CC=C6)OC(F)(F)F
CHEMBL578189 cxcr3_human Human No 9.0 IC50 = 1.1 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1921878 cxcr3_human Human No 8.9 IC50 = 1.2 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
547 6 2 8 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC5CC5
CHEMBL3116488 cxcr3_human Human No 8.9 IC50 = 1.2 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
555 7 2 11 3.4 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C)C5=NN=C(O5)NCC
CHEMBL3116496 cxcr3_human Human No 8.9 IC50 = 1.2 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
539 7 1 9 4.0 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C4=NC=C(N=C4C)C5=NN=C(O5)NCC
CHEMBL1921878 cxcr3_human Human No 8.9 IC50 = 1.2 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
547 6 2 8 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC5CC5
CHEMBL1921896 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
525 6 1 6 4.3 CCC1CN(C(CN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL570858 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)C(F)(F)F
CHEMBL3116481 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
562 5 3 12 2.6 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC(=C(N=C4Cl)C5=NN=C(O5)N)N
CHEMBL3116469 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
519 6 1 6 4.5 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C5=NCCN5)Cl
CHEMBL1921896 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
525 6 1 6 4.3 CCC1CN(C(CN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL570858 cxcr3_human Human No 8.9 IC50 = 1.3 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)C(F)(F)F
CHEMBL570857 cxcr3_human Human No 8.9 IC50 = 1.4 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
631 10 0 11 4.6 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)N(C)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL3116474 cxcr3_human Human No 8.9 IC50 = 1.4 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
519 6 0 8 5.0 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C5=NN=CO5)Cl
CHEMBL570857 cxcr3_human Human No 8.9 IC50 = 1.4 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
631 10 0 11 4.6 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)N(C)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1921877 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
564 6 2 8 4.4 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC(C)(C)C
CHEMBL1921871 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
577 7 2 9 4.6 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NC5CCOC5=O)N
CHEMBL1921883 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
555 5 2 11 3.3 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)NC
CHEMBL3116489 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
609 7 2 14 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C5=NN=C(O5)NCC
CHEMBL1921877 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
564 6 2 8 4.4 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4Cl)C(=O)NC(C)(C)C
CHEMBL1921871 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
577 7 2 9 4.6 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NC5CCOC5=O)N
CHEMBL1921883 cxcr3_human Human No 8.8 IC50 = 1.5 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
555 5 2 11 3.3 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)NC
CHEMBL1681882 cxcr3_rat Rat No 8.8 IC50 = 1.6 Funct
Antagonist activity at rat CXCR3Antagonist activity at rat CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL578188 cxcr3_human Human No 8.8 IC50 = 1.6 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
602 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1681882 cxcr3_rat Rat No 8.8 IC50 = 1.6 Funct
Antagonist activity at rat CXCR3Antagonist activity at rat CXCR3
522 7 1 6 5.2 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NCC)Cl
CHEMBL3116485 cxcr3_human Human No 8.8 IC50 = 1.6 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
576 6 3 12 3.3 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC(=C(N=C4Cl)C5=NN=C(O5)NC)N
CHEMBL3116501 cxcr3_human Human No 8.8 IC50 = 1.6 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
508 5 1 6 4.0 CCC1CN(C(CN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C)C4=NC=C(N=C4C)C5=NC=CN5
CHEMBL578188 cxcr3_human Human No 8.8 IC50 = 1.6 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
602 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL576098 cxcr3_human Human No 8.8 IC50 = 1.7 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=CC=C6)C(F)(F)F
CHEMBL576098 cxcr3_human Human No 8.8 IC50 = 1.7 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=CC=C6)C(F)(F)F
CHEMBL1921884 cxcr3_human Human No 8.7 IC50 = 1.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
581 6 2 11 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)NC5CC5
CHEMBL269932 cxcr3_human Human No 8.7 IC50 = 1.8 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
527 9 0 8 4.7 CCOC1=CC=C(C=C1)N2C=CN=C2C(C)N(CC3=CN=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3116495 cxcr3_human Human No 8.8 IC50 = 1.8 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
524 5 2 8 3.5 CCC1CN(C(CN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C)C4=NC=C(N=C4C)C5=NC=CN5
CHEMBL3116498 cxcr3_human Human No 8.8 IC50 = 1.8 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
607 7 1 12 4.9 CCC1CN(C(CN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C)C4=NC=C(N=C4C(F)(F)F)C5=NN=C(O5)NCC
CHEMBL1921884 cxcr3_human Human No 8.8 IC50 = 1.8 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
581 6 2 11 3.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)NC5CC5
CHEMBL269932 cxcr3_human Human No 8.8 IC50 = 1.8 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
527 9 0 8 4.7 CCOC1=CC=C(C=C1)N2C=CN=C2C(C)N(CC3=CN=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1921869 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
615 10 4 11 2.9 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCNS(=O)(=O)N)N
CHEMBL1921861 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
522 7 3 8 3.4 CCC1CN(CCN1C2CCN(CC2)C(CO)C3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N
CHEMBL1921887 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
527 6 2 8 3.4 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL1921882 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
541 5 2 11 2.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)N
CHEMBL1921869 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
615 10 4 11 2.9 CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)NCCNS(=O)(=O)N)N
CHEMBL1921861 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
522 7 3 8 3.4 CCC1CN(CCN1C2CCN(CC2)C(CO)C3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N
CHEMBL1921887 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
527 6 2 8 3.4 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C)C(=O)NC5CC5
CHEMBL1921882 cxcr3_human Human No 8.7 IC50 = 1.9 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
541 5 2 11 2.9 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=C(N=C(C=C3)Cl)N)C4=NC=C(N=C4C(F)(F)F)C(=O)N
CHEMBL1077824 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
640 10 0 10 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4CCCN4C(C)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL401868 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPRAntagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPR
572 9 1 4 6.0 C1CC1N(CCCN2C3=C(C=CC=C3Cl)N(C2=N)CC(=O)C4=CC=C(C=C4)Cl)C(=O)C5=CC=CC6=C5N=CC=C6
CHEMBL1808996 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
400 2 2 2 2.3 CN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1808996 cxcr3_mouse Mouse No 8.0 IC50 = 10 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
400 2 2 2 2.3 CN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1809025 cxcr3_mouse Mouse No 8.0 IC50 = 10 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 3 2.8 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CS6
CHEMBL578197 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL400736 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
588 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC=NC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL400736 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
588 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC=NC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578197 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL571081 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
646 10 0 12 4.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)OC)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578188 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
602 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL257908 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
607 11 1 10 3.2 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)CO)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077824 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
640 10 0 10 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4CCCN4C(C)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL401868 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPRAntagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPR
572 9 1 4 6.0 C1CC1N(CCCN2C3=C(C=CC=C3Cl)N(C2=N)CC(=O)C4=CC=C(C=C4)Cl)C(=O)C5=CC=CC6=C5N=CC=C6
CHEMBL1808996 cxcr3_human Human No 8.0 IC50 = 10 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
400 2 2 2 2.3 CN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1808996 cxcr3_mouse Mouse No 8.0 IC50 = 10 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
400 2 2 2 2.3 CN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1809025 cxcr3_mouse Mouse No 8.0 IC50 = 10 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 3 2.8 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CS6
CHEMBL578197 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL400736 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
588 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC=NC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL400736 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
588 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC=NC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578197 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL571081 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
646 10 0 12 4.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)OC)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578188 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
602 9 0 10 4.5 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL257908 cxcr3_human Human No 8.0 IC50 = 10 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
607 11 1 10 3.2 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)CO)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL256891 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPRAntagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPR
503 10 1 3 5.3 CCC1=C2C(=CC=C1)N(C(=N)N2CCCN(C)C(=O)CC3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)Cl
CHEMBL574831 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assay
443 4 2 2 4.2 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=C(C=C5)C
CHEMBL577108 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
602 9 0 10 4.9 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC(=NC2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL397020 cxcr3_human Human No 7.0 IC50 = 100 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
567 7 0 9 5.5 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CC4=NC=CS4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL256226 cxcr3_human Human No 7.0 IC50 = 100 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
314 3 1 2 3.4 CC1=C2C(=CC=C1)N(C(=N)N2C)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL199839 cxcr3_human Human No 7.0 IC50 = 100 Funct
Inhibition of CXCL11-induced CXCR3 mediated T-cell migrationInhibition of CXCL11-induced CXCR3 mediated T-cell migration
617 8 3 4 5.8 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL256891 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPRAntagonist activity at human CXCR3 expressed in CHO cell membrane assessed as inhibition of calcium flux by FLIPR
503 10 1 3 5.3 CCC1=C2C(=CC=C1)N(C(=N)N2CCCN(C)C(=O)CC3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)Cl
CHEMBL574831 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assay
443 4 2 2 4.2 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=C(C=C5)C
CHEMBL577108 cxcr3_human Human No 7.0 IC50 = 100 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
602 9 0 10 4.9 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CC(=NC2=N1)C)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL397020 cxcr3_human Human No 7.0 IC50 = 100 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
567 7 0 9 5.5 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CC4=NC=CS4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL256226 cxcr3_human Human No 7.0 IC50 = 100 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
314 3 1 2 3.4 CC1=C2C(=CC=C1)N(C(=N)N2C)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL199839 cxcr3_human Human No 7.0 IC50 = 100 Funct
Inhibition of CXCL11-induced CXCR3 mediated T-cell migrationInhibition of CXCL11-induced CXCR3 mediated T-cell migration
617 8 3 4 5.8 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL498199 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
457 4 2 4 3.5 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC(=CC=C3)O)CC4=CC=C(C=C4)Br
CHEMBL498555 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
501 6 0 4 4.7 CSCN1C(=O)CCC(C1=O)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL496771 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
442 4 1 4 2.7 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CN=CC=C3)CC4=CC=C(C=C4)Br
CHEMBL464083 cxcr3_mouse Mouse No 6.0 IC50 = 1000 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
461 4 0 10 2.5 CC1CN(CCN1C2=NC=C(C=N2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL3697083 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.5 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)CCCN5C(=O)CCC5=O
CHEMBL3697082 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
567 11 1 6 2.5 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)CCCN5C(=O)CCC5=O
CHEMBL256647 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
314 3 1 2 3.4 CC1=CC2=C(C=C1)N(C(=N)N2C)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL273013 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
402 6 0 3 3.0 CN1C2=CC=CC=C2N(C1=NCCOC)CC(=O)C3=CC=C(C=C3)Br
CHEMBL498199 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
457 4 2 4 3.5 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC(=CC=C3)O)CC4=CC=C(C=C4)Br
CHEMBL498555 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
501 6 0 4 4.7 CSCN1C(=O)CCC(C1=O)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL496771 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
442 4 1 4 2.7 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CN=CC=C3)CC4=CC=C(C=C4)Br
CHEMBL464083 cxcr3_mouse Mouse No 6.0 IC50 = 1000 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
461 4 0 10 2.5 CC1CN(CCN1C2=NC=C(C=N2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL3697083 cxcr3_human Human No 6.0 IC50 = 1000 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.5 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)CCCN5C(=O)CCC5=O
CHEMBL256647 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
314 3 1 2 3.4 CC1=CC2=C(C=C1)N(C(=N)N2C)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL273013 cxcr3_human Human No 6.0 IC50 = 1000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
402 6 0 3 3.0 CN1C2=CC=CC=C2N(C1=NCCOC)CC(=O)C3=CC=C(C=C3)Br
CHEMBL1809034 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
431 3 2 3 1.9 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NCC6=CC=CO6
CHEMBL395747 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
621 8 0 9 4.5 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)S(=O)(=O)C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL401888 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
653 11 0 9 5.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C4CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL370482 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Inhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligandInhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligand
516 14 0 5 6.2 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3C#N
CHEMBL1809034 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
431 3 2 3 1.9 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NCC6=CC=CO6
CHEMBL395747 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
621 8 0 9 4.5 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)S(=O)(=O)C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL401888 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
653 11 0 9 5.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C4CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL370482 cxcr3_human Human No 5.0 IC50 = 10000 Funct
Inhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligandInhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligand
516 14 0 5 6.2 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3C#N
CHEMBL1809004 cxcr3_human Human No 6.0 IC50 = 1010 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
442 2 3 3 1.7 C1CN(CCN1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809004 cxcr3_human Human No 6.0 IC50 = 1010 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
442 2 3 3 1.7 C1CN(CCN1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1939557 cxcr3_human Human No 7.0 IC50 = 102 Funct
Antagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serumAntagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serum
625 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3697098 cxcr3_human Human No 7.0 IC50 = 102 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
532 11 1 7 1.3 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC=C(C=C3)C#N)OCCN4C(=O)CCC4=O
CHEMBL1939557 cxcr3_human Human No 7.0 IC50 = 102 Funct
Antagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serumAntagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serum
625 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3697098 cxcr3_human Human No 7.0 IC50 = 102 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
532 11 1 7 1.3 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC=C(C=C3)C#N)OCCN4C(=O)CCC4=O
CHEMBL3700571 cxcr3_human Human No 7.0 IC50 = 104 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
549 11 1 7 1.6 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL3700571 cxcr3_human Human No 7.0 IC50 = 104 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
549 11 1 7 1.6 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL3697163 cxcr3_human Human No 7.0 IC50 = 105 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
513 10 1 6 1.7 CC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)C)OCCN4C(=O)CCC4=O
CHEMBL3697163 cxcr3_human Human No 7.0 IC50 = 105 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
513 10 1 6 1.7 CC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)C)OCCN4C(=O)CCC4=O
CHEMBL3700592 cxcr3_human Human No 6.0 IC50 = 1060 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
541 11 1 7 1.2 COC1=C(C=CC(=C1)CN(CC2CC(C2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3700592 cxcr3_human Human No 6.0 IC50 = 1060 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
541 11 1 7 1.2 COC1=C(C=CC(=C1)CN(CC2CC(C2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL1939558 cxcr3_human Human No 7.0 IC50 = 107 Funct
Antagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serumAntagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serum
625 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL3697121 cxcr3_human Human No 7.0 IC50 = 107 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
537 12 1 7 1.6 CC1=CC=C(C=C1)C(C)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL1939558 cxcr3_human Human No 7.0 IC50 = 107 Funct
Antagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serumAntagonist activity at CXCR3 assessed as inhibition of ITAC-mediated cell migration in presence of 100% human serum
625 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL3697121 cxcr3_human Human No 7.0 IC50 = 107 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
537 12 1 7 1.6 CC1=CC=C(C=C1)C(C)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697136 cxcr3_human Human No 7.0 IC50 = 108 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697136 cxcr3_human Human No 7.0 IC50 = 108 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL1083956 cxcr3_human Human No 6.0 IC50 = 1080 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
425 7 1 8 2.4 C1=CC=NC(=C1)CN(CC2=CC(=C(C=C2)C(=O)O)F)S(=O)(=O)C3=CC=C(C=C3)C#N
CHEMBL1083956 cxcr3_human Human No 6.0 IC50 = 1080 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
425 7 1 8 2.4 C1=CC=NC(=C1)CN(CC2=CC(=C(C=C2)C(=O)O)F)S(=O)(=O)C3=CC=C(C=C3)C#N
CHEMBL3697162 cxcr3_human Human No 6.0 IC50 = 1090 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
527 10 1 7 1.0 COC1=C(C=CC(=C1)CN(C2CCC3=C2C=CC(=C3)Cl)C4CC(C4)C(=O)O)OCCN5C(=O)CCC5=O
CHEMBL3697162 cxcr3_human Human No 6.0 IC50 = 1090 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
527 10 1 7 1.0 COC1=C(C=CC(=C1)CN(C2CCC3=C2C=CC(=C3)Cl)C4CC(C4)C(=O)O)OCCN5C(=O)CCC5=O
CHEMBL1809028 cxcr3_human Human No 8.0 IC50 = 11 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 2 3.1 C1CCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL1809024 cxcr3_mouse Mouse No 8.0 IC50 = 11 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 3 2.5 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CSC=C6
CHEMBL231486 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
568 7 0 8 5.0 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)C#N)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077812 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
587 9 0 8 5.6 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=CC=C5)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578189 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL403379 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
584 12 0 8 6.2 CCOCCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)OCC)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL272290 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CN=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL401662 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
595 10 1 8 6.1 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3CCCN3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL1809028 cxcr3_human Human No 8.0 IC50 = 11 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 2 3.1 C1CCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL1809024 cxcr3_mouse Mouse No 8.0 IC50 = 11 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
433 2 2 3 2.5 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CSC=C6
CHEMBL231486 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
568 7 0 8 5.0 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)C#N)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077812 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
587 9 0 8 5.6 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=CC=C5)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578189 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL403379 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
584 12 0 8 6.2 CCOCCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)OCC)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL272290 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CN=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL401662 cxcr3_human Human No 8.0 IC50 = 11 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
595 10 1 8 6.1 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3CCCN3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL1681832 cxcr3_human Human No 7.0 IC50 = 110 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
490 5 1 5 4.6 CC1CN(CCN1C2CCN(CC2)C(C)C3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL498556 cxcr3_human Human No 7.0 IC50 = 110 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
455 4 0 2 4.9 CC(=O)N1CCCC(C1)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL1077821 cxcr3_human Human No 7.0 IC50 = 110 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
606 9 0 10 5.0 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=CC=N3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1681832 cxcr3_human Human No 7.0 IC50 = 110 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
490 5 1 5 4.6 CC1CN(CCN1C2CCN(CC2)C(C)C3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL1077821 cxcr3_human Human No 7.0 IC50 = 110 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
606 9 0 10 5.0 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=CC=N3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL272060 cxcr3_human Human No 6.0 IC50 = 1100 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
328 5 1 2 3.9 CCCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL401868 cxcr3_mouse Mouse No 6.0 IC50 = 1100 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
572 9 1 4 6.0 C1CC1N(CCCN2C3=C(C=CC=C3Cl)N(C2=N)CC(=O)C4=CC=C(C=C4)Cl)C(=O)C5=CC=CC6=C5N=CC=C6
CHEMBL272060 cxcr3_human Human No 6.0 IC50 = 1100 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
328 5 1 2 3.9 CCCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL401868 cxcr3_mouse Mouse No 6.0 IC50 = 1100 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
572 9 1 4 6.0 C1CC1N(CCCN2C3=C(C=CC=C3Cl)N(C2=N)CC(=O)C4=CC=C(C=C4)Cl)C(=O)C5=CC=CC6=C5N=CC=C6
CHEMBL258126 cxcr3_human Human No 5.0 IC50 = 11000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
343 4 0 6 2.2 CS(=O)C1=NC2=CC=CC=C2N1CC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
CHEMBL272742 cxcr3_human Human No 5.0 IC50 = 11000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
330 3 1 1 3.7 CN1C2=CC=CC=C2N(C1=N)CCC3=CC=C(C=C3)Br
CHEMBL258126 cxcr3_human Human No 5.0 IC50 = 11000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
343 4 0 6 2.2 CS(=O)C1=NC2=CC=CC=C2N1CC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
CHEMBL272742 cxcr3_human Human No 5.0 IC50 = 11000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
330 3 1 1 3.7 CN1C2=CC=CC=C2N(C1=N)CCC3=CC=C(C=C3)Br
CHEMBL1809006 cxcr3_mouse Mouse No 7.0 IC50 = 112 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
456 2 2 3 2.2 CN1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697059 cxcr3_human Human No 7.0 IC50 = 112 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
584 11 1 7 2.1 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CN(C5=O)C)Cl
CHEMBL1809006 cxcr3_mouse Mouse No 7.0 IC50 = 112 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
456 2 2 3 2.2 CN1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697059 cxcr3_human Human No 7.0 IC50 = 112 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
584 11 1 7 2.1 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CN(C5=O)C)Cl
CHEMBL404841 cxcr3_human Human No 6.0 IC50 = 1124 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
604 12 0 9 4.2 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3C=CC(=N3)C(F)(F)F)C4=CC=CC=C4
CHEMBL404841 cxcr3_human Human No 6.0 IC50 = 1124 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
604 12 0 9 4.2 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3C=CC(=N3)C(F)(F)F)C4=CC=CC=C4
CHEMBL1083954 cxcr3_human Human No 6.0 IC50 = 1132 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
435 7 1 7 3.3 C1=CC=NC(=C1)CN(CC2=CC(=C(C=C2)C(=O)O)F)S(=O)(=O)C3=CC=C(C=C3)Cl
CHEMBL1083954 cxcr3_human Human No 6.0 IC50 = 1132 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
435 7 1 7 3.3 C1=CC=NC(=C1)CN(CC2=CC(=C(C=C2)C(=O)O)F)S(=O)(=O)C3=CC=C(C=C3)Cl
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonist activity at CXCR3 assessed as ITAC-mediated migration of human PBMC in presence of 100% human plasmaAntagonist activity at CXCR3 assessed as ITAC-mediated migration of human PBMC in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL399084 cxcr3_human Human No 6.9 IC50 = 115 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
598 9 0 9 5.6 CCS(=O)(=O)CCN(C(C)C1=CC2=CC=CC=C2N=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonist activity at CXCR3 assessed as ITAC-mediated migration of human PBMC in presence of 100% human plasmaAntagonist activity at CXCR3 assessed as ITAC-mediated migration of human PBMC in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL253431 cxcr3_human Human No 6.9 IC50 = 115 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL399084 cxcr3_human Human No 6.9 IC50 = 115 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
598 9 0 9 5.6 CCS(=O)(=O)CCN(C(C)C1=CC2=CC=CC=C2N=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1085998 cxcr3_human Human No 5.9 IC50 = 1152 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
466 10 1 6 3.0 COC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC=C(C=C2)C(=O)NCC3CC3)CC4=CN=CC=C4
CHEMBL1085998 cxcr3_human Human No 5.9 IC50 = 1152 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
466 10 1 6 3.0 COC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC=C(C=C2)C(=O)NCC3CC3)CC4=CN=CC=C4
CHEMBL3697060 cxcr3_human Human No 6.9 IC50 = 116 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
577 11 1 6 2.7 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)Cl
CHEMBL3697060 cxcr3_human Human No 6.9 IC50 = 116 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
577 11 1 6 2.7 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)Cl
CHEMBL1809009 cxcr3_human Human No 5.9 IC50 = 1160 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
471 2 2 3 2.8 CC1CN(CC(O1)C)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809009 cxcr3_human Human No 5.9 IC50 = 1160 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
471 2 2 3 2.8 CC1CN(CC(O1)C)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL404898 cxcr3_human Human No 5.9 IC50 = 1179 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CC=CC=N3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL404898 cxcr3_human Human No 5.9 IC50 = 1179 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CC=CC=N3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL1808998 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
431 4 3 3 1.7 CN(CCO)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1809014 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 3 3 1.9 C1CN(CC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809008 cxcr3_mouse Mouse No 7.9 IC50 = 12 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 2 3 2.0 C1COCCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL578189 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1939559 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
651 7 0 10 5.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1938408 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
642 7 0 11 4.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL571080 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
630 9 0 11 4.1 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)C)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL402989 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
627 11 0 11 4.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1809003 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
439 2 2 2 3.2 C1CC=CN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1808998 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
431 4 3 3 1.7 CN(CCO)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1809014 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 3 3 1.9 C1CN(CC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809008 cxcr3_mouse Mouse No 7.9 IC50 = 12 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 2 3 2.0 C1COCCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL578189 cxcr3_human Human No 7.9 IC50 = 12 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 10 0 10 5.0 CCC1=NC=CN2C1=NC(=C2C3=CC=C(C=C3)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1939559 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
651 7 0 10 5.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1938408 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
642 7 0 11 4.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL571080 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
630 9 0 11 4.1 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)C)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL402989 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
627 11 0 11 4.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1809003 cxcr3_human Human No 7.9 IC50 = 12 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
439 2 2 2 3.2 C1CC=CN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL495531 cxcr3_human Human No 6.9 IC50 = 120 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
477 4 1 5 4.0 C1CN(CCC1C2(CCC(=O)NC2=O)C3=C(C=C(C=C3)F)F)CC4=CC=C(C=C4)Br
CHEMBL3700576 cxcr3_human Human No 6.9 IC50 = 120 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
533 11 1 8 1.0 CC(C1=CC(=C(C=C1)Cl)F)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL381227 cxcr3_human Human No 6.9 IC50 = 120 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
583 8 3 4 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=CC=C(C=C3)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL3700576 cxcr3_human Human No 6.9 IC50 = 120 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
533 11 1 8 1.0 CC(C1=CC(=C(C=C1)Cl)F)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL381227 cxcr3_human Human No 6.9 IC50 = 120 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
583 8 3 4 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=CC=C(C=C3)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL3700573 cxcr3_human Human No 5.9 IC50 = 1200 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
547 11 1 6 2.4 CCC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)Cl)OCCN4C(=O)CCC4=O
CHEMBL3697057 cxcr3_human Human No 5.9 IC50 = 1200 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
589 10 1 6 2.7 CN1CC(=O)N(C1=O)CCOC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)Cl
CHEMBL271081 cxcr3_human Human No 5.9 IC50 = 1200 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
386 8 1 4 3.2 CCOC(=O)CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL3700573 cxcr3_human Human No 5.9 IC50 = 1200 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
547 11 1 6 2.4 CCC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)Cl)OCCN4C(=O)CCC4=O
CHEMBL3697057 cxcr3_human Human No 5.9 IC50 = 1200 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
589 10 1 6 2.7 CN1CC(=O)N(C1=O)CCOC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)Cl
CHEMBL271081 cxcr3_human Human No 5.9 IC50 = 1200 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
386 8 1 4 3.2 CCOC(=O)CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL3697128 cxcr3_human Human No 6.9 IC50 = 121 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
573 12 1 7 2.8 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)F)OCCN4C(=O)CCC4=O
CHEMBL3697102 cxcr3_human Human No 6.9 IC50 = 121 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
555 12 1 6 2.8 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL254082 cxcr3_human Human No 6.9 IC50 = 121 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
599 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=CC=CC=C2N=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3697128 cxcr3_human Human No 6.9 IC50 = 121 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
573 12 1 7 2.8 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC(=C(C=C3)Cl)F)OCCN4C(=O)CCC4=O
CHEMBL3697102 cxcr3_human Human No 6.9 IC50 = 121 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
555 12 1 6 2.8 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL254082 cxcr3_human Human No 6.9 IC50 = 121 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
599 9 0 10 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=CC=CC=C2N=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3697069 cxcr3_human Human No 6.9 IC50 = 123 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
562 11 1 6 2.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)Cl
CHEMBL3697069 cxcr3_human Human No 6.9 IC50 = 123 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
562 11 1 6 2.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)Cl
CHEMBL3697087 cxcr3_human Human No 5.9 IC50 = 1240 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
582 11 1 6 2.7 CN1CC(=O)N(C1=O)CCCC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)OC
CHEMBL3697087 cxcr3_human Human No 5.9 IC50 = 1240 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
582 11 1 6 2.7 CN1CC(=O)N(C1=O)CCCC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)OC
CHEMBL464083 cxcr3_human Human No 6.9 IC50 = 125.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
461 4 0 10 2.5 CC1CN(CCN1C2=NC=C(C=N2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL464083 cxcr3_human Human No 6.9 IC50 = 125.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
461 4 0 10 2.5 CC1CN(CCN1C2=NC=C(C=N2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL199408 cxcr3_human Human No 5.9 IC50 = 1250 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
534 7 3 4 4.1 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCC3=CC=CC=C3)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL199408 cxcr3_human Human No 5.9 IC50 = 1250 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
534 7 3 4 4.1 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCC3=CC=CC=C3)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL1681859 cxcr3_human Human No 4.9 IC50 = 12500 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
476 5 1 5 4.2 CC1CN(CCN1C2CCN(CC2)C3=C(C=C(C=N3)C(=O)NC)Cl)CC4=CC=C(C=C4)Cl
CHEMBL1681859 cxcr3_human Human No 4.9 IC50 = 12500 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
476 5 1 5 4.2 CC1CN(CCN1C2CCN(CC2)C3=C(C=C(C=N3)C(=O)NC)Cl)CC4=CC=C(C=C4)Cl
CHEMBL464081 cxcr3_mouse Mouse No 5.9 IC50 = 1258.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
446 4 0 9 2.7 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL464081 cxcr3_mouse Mouse No 5.9 IC50 = 1258.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
446 4 0 9 2.7 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL498012 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
431 4 1 3 4.4 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC(=C(C=C4)Cl)Cl
CHEMBL498198 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
583 6 2 6 2.8 CN(C(=O)C1=CC(=CC=C1)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br)N5CCNCC5
CHEMBL514259 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
542 8 3 5 2.8 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC(=C3)C(=O)NCCCO)CC4=CC=C(C=C4)Br
CHEMBL522551 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
459 4 1 4 3.9 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=C(C=C3)F)CC4=CC=C(C=C4)Br
CHEMBL498012 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
431 4 1 3 4.4 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC(=C(C=C4)Cl)Cl
CHEMBL498198 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
583 6 2 6 2.8 CN(C(=O)C1=CC(=CC=C1)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br)N5CCNCC5
CHEMBL514259 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
542 8 3 5 2.8 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC(=C3)C(=O)NCCCO)CC4=CC=C(C=C4)Br
CHEMBL522551 cxcr3_human Human No 5.9 IC50 = 1260 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
459 4 1 4 3.9 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=C(C=C3)F)CC4=CC=C(C=C4)Br
CHEMBL578197 cxcr3_human Human No 6.9 IC50 = 129 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL272919 cxcr3_human Human No 6.9 IC50 = 129 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CC=NC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL578197 cxcr3_human Human No 6.9 IC50 = 129 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
616 9 0 11 3.7 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL272919 cxcr3_human Human No 6.9 IC50 = 129 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
603 10 0 8 6.4 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3=CC=NC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL1082649 cxcr3_human Human No 5.9 IC50 = 1295 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
474 7 1 6 4.5 C1=CC(=CC(=C1)Cl)CN(CC2=CC=C(C=C2)C3=NNN=N3)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1083315 cxcr3_human Human No 5.9 IC50 = 1295 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
539 9 1 4 6.1 C1=CC=C(C=C1)CN(CC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)Cl)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1082649 cxcr3_human Human No 5.9 IC50 = 1295 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
474 7 1 6 4.5 C1=CC(=CC(=C1)Cl)CN(CC2=CC=C(C=C2)C3=NNN=N3)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1083315 cxcr3_human Human No 5.9 IC50 = 1295 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
539 9 1 4 6.1 C1=CC=C(C=C1)CN(CC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)Cl)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1809000 cxcr3_rat Rat No 7.9 IC50 = 13 Funct
Antagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometryAntagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometry
441 2 2 2 3.2 C1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1082388 cxcr3_human Human No 7.9 IC50 = 13 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
523 9 1 6 3.9 C1CC1(C2=CC=CC=C2)NC(=O)C3=CC=C(C=C3)CN(CC4=CC=CC=N4)S(=O)(=O)C5=CC=C(C=C5)C#N
CHEMBL1809001 cxcr3_mouse Mouse No 7.9 IC50 = 13 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
455 2 2 2 3.5 C1CCCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697049 cxcr3_human Human No 7.9 IC50 = 13 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL578192 cxcr3_mouse Mouse No 7.9 IC50 = 13 Funct
Displacement of ITAC from CXCR3 receptor in mouse whole blood assayDisplacement of ITAC from CXCR3 receptor in mouse whole blood assay
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL230560 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
561 7 0 8 5.4 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077810 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
588 9 0 9 4.6 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=NC=C(C=C5)C(F)(F)F
CHEMBL3697049 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL1939553 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
602 8 0 11 3.3 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CCS(=O)(=O)C)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1939560 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
651 7 0 10 5.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL576096 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)OC(F)(F)F
CHEMBL1809000 cxcr3_rat Rat No 7.9 IC50 = 13 Funct
Antagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometryAntagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometry
441 2 2 2 3.2 C1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1082388 cxcr3_human Human No 7.9 IC50 = 13 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
523 9 1 6 3.9 C1CC1(C2=CC=CC=C2)NC(=O)C3=CC=C(C=C3)CN(CC4=CC=CC=N4)S(=O)(=O)C5=CC=C(C=C5)C#N
CHEMBL1809001 cxcr3_mouse Mouse No 7.9 IC50 = 13 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
455 2 2 2 3.5 C1CCCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697049 cxcr3_human Human No 7.9 IC50 = 13 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL578192 cxcr3_mouse Mouse No 7.9 IC50 = 13 Funct
Displacement of ITAC from CXCR3 receptor in mouse whole blood assayDisplacement of ITAC from CXCR3 receptor in mouse whole blood assay
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL230560 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
561 7 0 8 5.4 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077810 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation countingDisplacement of [125I]-1P10 from human CXCR3 expressed in PBMC after 2 hrs in RPMI buffer by scintillation counting
588 9 0 9 4.6 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=NC=C(C=C5)C(F)(F)F
CHEMBL1939553 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-IP-10 from CXCR3Displacement of [125I]-IP-10 from CXCR3
602 8 0 11 3.3 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CCS(=O)(=O)C)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1939560 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
651 7 0 10 5.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)Cl)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL576096 cxcr3_human Human No 7.9 IC50 = 13 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
652 9 0 10 5.3 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)OC(F)(F)F
CHEMBL199321 cxcr3_human Human No 6.9 IC50 = 130 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
589 8 3 5 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC=CS4
CHEMBL199321 cxcr3_human Human No 6.9 IC50 = 130 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
589 8 3 5 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC=CS4
CHEMBL270222 cxcr3_human Human No 5.9 IC50 = 1300 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
385 6 1 3 2.6 CC(=O)N(C)CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL270222 cxcr3_human Human No 5.9 IC50 = 1300 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
385 6 1 3 2.6 CC(=O)N(C)CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=C(C=C3)Cl
CHEMBL370167 cxcr3_human Human No 4.9 IC50 = 13000 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
618 9 2 5 6.4 CCOC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL370167 cxcr3_human Human No 4.9 IC50 = 13000 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
618 9 2 5 6.4 CCOC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL1081164 cxcr3_human Human No 6.9 IC50 = 131 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
640 8 0 10 4.6 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCN(CC4)C(=O)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL3697078 cxcr3_human Human No 6.9 IC50 = 131 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
565 12 1 8 1.4 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL1809006 cxcr3_human Human No 6.9 IC50 = 131 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
456 2 2 3 2.2 CN1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1081164 cxcr3_human Human No 6.9 IC50 = 131 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
640 8 0 10 4.6 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCN(CC4)C(=O)C)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL3697078 cxcr3_human Human No 6.9 IC50 = 131 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
565 12 1 8 1.4 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL1809006 cxcr3_human Human No 6.9 IC50 = 131 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
456 2 2 3 2.2 CN1CCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL10309 cxcr3_human Human No 5.9 IC50 = 1330 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
441 4 1 3 3.8 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=C(C=C4)Br
CHEMBL10309 cxcr3_human Human No 5.9 IC50 = 1330 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
441 4 1 3 3.8 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=C(C=C4)Br
CHEMBL395748 cxcr3_human Human No 5.9 IC50 = 1370 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
587 8 1 9 4.8 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)C(=O)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL395748 cxcr3_human Human No 5.9 IC50 = 1370 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
587 8 1 9 4.8 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)C(=O)O)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL3116471 cxcr3_human Human No 5.9 IC50 = 1376 Funct
Binding affinity to human CXCR3 receptorBinding affinity to human CXCR3 receptor
519 6 1 8 4.7 CCC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C5=NNN=N5)Cl
CHEMBL1809001 cxcr3_human Human No 7.9 IC50 = 14 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
455 2 2 2 3.5 C1CCCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809029 cxcr3_human Human No 7.9 IC50 = 14 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
447 2 2 2 3.6 C1CCCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL1808999 cxcr3_mouse Mouse No 7.9 IC50 = 14 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
412 2 2 2 2.5 C1CN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL397678 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
573 8 0 8 5.2 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)OC)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077832 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
620 10 0 10 4.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=C[N+](=CC=C4)[O-])C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL437401 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
609 10 0 8 6.6 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3CCCN3C)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL403036 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1809011 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
457 2 3 3 2.2 C1CN(CCC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809040 cxcr3_rat Rat No 7.9 IC50 = 14 Funct
Ex vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometryEx vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometry
524 5 1 3 3.2 C1CCN(C1)CCN2C=C3CC4C(=CC(CN4C(=O)NC5=CC=CC=C5)C(=O)N6CCCC6)C7=C3C2=CC=C7
CHEMBL1809001 cxcr3_human Human No 7.9 IC50 = 14 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
455 2 2 2 3.5 C1CCCN(CC1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809029 cxcr3_human Human No 7.9 IC50 = 14 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
447 2 2 2 3.6 C1CCCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL1808999 cxcr3_mouse Mouse No 7.9 IC50 = 14 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
412 2 2 2 2.5 C1CN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL397678 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
573 8 0 8 5.2 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)OC)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)C(F)(F)F
CHEMBL1077832 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
620 10 0 10 4.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=C[N+](=CC=C4)[O-])C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL437401 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
609 10 0 8 6.6 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CC3CCCN3C)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F)C5=CC=CC=C5
CHEMBL403036 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
613 10 0 9 5.1 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C3=CC=CC=C3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1809011 cxcr3_human Human No 7.9 IC50 = 14 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
457 2 3 3 2.2 C1CN(CCC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809040 cxcr3_rat Rat No 7.9 IC50 = 14 Funct
Ex vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometryEx vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometry
524 5 1 3 3.2 C1CCN(C1)CCN2C=C3CC4C(=CC(CN4C(=O)NC5=CC=CC=C5)C(=O)N6CCCC6)C7=C3C2=CC=C7
CHEMBL230664 cxcr3_human Human No 6.9 IC50 = 140 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
603 10 0 9 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL1681877 cxcr3_human Human No 6.9 IC50 = 140 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
520 7 1 7 3.7 CNC(=O)C1=CC(=C(N=C1)N2CCN(C(C2)C(=O)OC)C3CCN(CC3)CC4=CC=C(C=C4)Cl)Cl
CHEMBL498556 cxcr3_human Human No 6.9 IC50 = 140 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
455 4 0 2 4.9 CC(=O)N1CCCC(C1)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL230664 cxcr3_human Human No 6.9 IC50 = 140 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
603 10 0 9 5.9 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL1681877 cxcr3_human Human No 6.9 IC50 = 140 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
520 7 1 7 3.7 CNC(=O)C1=CC(=C(N=C1)N2CCN(C(C2)C(=O)OC)C3CCN(CC3)CC4=CC=C(C=C4)Cl)Cl
CHEMBL1681857 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
588 7 1 7 4.9 C1CN(CCC1N2CCN(CC2=O)C3=C(C=C(C=N3)C(=O)NCC4=CC(=C(C=C4)F)F)Cl)CC5=CC=C(C=C5)Cl
CHEMBL230020 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
531 14 0 7 5.7 CCCCCCCCS(=O)(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL374820 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=CC=N3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL255583 cxcr3_mouse Mouse No 5.9 IC50 = 1400 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
509 9 1 3 5.1 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)CC4=CC=CC=C4
CHEMBL1681857 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
588 7 1 7 4.9 C1CN(CCC1N2CCN(CC2=O)C3=C(C=C(C=N3)C(=O)NCC4=CC(=C(C=C4)F)F)Cl)CC5=CC=C(C=C5)Cl
CHEMBL230020 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
531 14 0 7 5.7 CCCCCCCCS(=O)(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL374820 cxcr3_human Human No 5.9 IC50 = 1400 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=CC=N3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL255583 cxcr3_mouse Mouse No 5.9 IC50 = 1400 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
509 9 1 3 5.1 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)CC4=CC=CC=C4
CHEMBL571082 cxcr3_human Human No 6.9 IC50 = 142 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
660 11 0 12 4.3 CCOC1=NC2=C(C=C1)C(=O)N(C(=N2)C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=C(C=C4)C#N
CHEMBL571082 cxcr3_human Human No 6.9 IC50 = 142 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
660 11 0 12 4.3 CCOC1=NC2=C(C=C1)C(=O)N(C(=N2)C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=C(C=C4)C#N
CHEMBL3697105 cxcr3_human Human No 6.8 IC50 = 143 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
598 13 1 7 2.6 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)C=CN(C4=O)C)OC
CHEMBL3697105 cxcr3_human Human No 6.9 IC50 = 143 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
598 13 1 7 2.6 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)C=CN(C4=O)C)OC
CHEMBL3697072 cxcr3_human Human No 5.8 IC50 = 1430 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
561 11 1 7 1.7 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)C=CCN5C(=O)CCC5=O)OC
CHEMBL3697072 cxcr3_human Human No 5.9 IC50 = 1430 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
561 11 1 7 1.7 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)C=CCN5C(=O)CCC5=O)OC
CHEMBL3697142 cxcr3_human Human No 6.8 IC50 = 144 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL397984 cxcr3_human Human No 6.8 IC50 = 144 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
604 10 0 10 4.8 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=NC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL3697142 cxcr3_human Human No 6.8 IC50 = 144 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL397984 cxcr3_human Human No 6.8 IC50 = 144 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
604 10 0 10 4.8 CCOC1=CC=C(C=C1)N2C(=O)C3=C(C=NC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL3697148 cxcr3_human Human No 6.8 IC50 = 145 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
523 12 1 8 0.2 CC(C1=CC2=C(C=C1)OCC2)N(CC3CC3C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL1809037 cxcr3_human Human No 6.8 IC50 = 145 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
527 6 1 4 3.6 CC(C)OC(=O)CN1C=C2CC3C(=CC(CN3C(=O)NC4=CC=CC=C4)C(=O)N5CCCC5)C6=C2C1=CC=C6
CHEMBL3697148 cxcr3_human Human No 6.8 IC50 = 145 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
523 12 1 8 0.2 CC(C1=CC2=C(C=C1)OCC2)N(CC3CC3C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL1809037 cxcr3_human Human No 6.8 IC50 = 145 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
527 6 1 4 3.6 CC(C)OC(=O)CN1C=C2CC3C(=CC(CN3C(=O)NC4=CC=CC=C4)C(=O)N5CCCC5)C6=C2C1=CC=C6
CHEMBL523748 cxcr3_human Human No 5.8 IC50 = 1450 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
476 4 1 3 4.4 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC(=CC=C3)Cl)CC4=CC=C(C=C4)Br
CHEMBL523748 cxcr3_human Human No 5.8 IC50 = 1450 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
476 4 1 3 4.4 C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC(=CC=C3)Cl)CC4=CC=C(C=C4)Br
CHEMBL3697120 cxcr3_human Human No 6.8 IC50 = 146 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
521 11 1 6 2.0 CC1=CC=C(C=C1)C(C)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL3700579 cxcr3_human Human No 6.8 IC50 = 146 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
578 12 1 7 2.2 CC(C1=CC2=C(CCC2)C=C1)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CN(C5=O)C)OC
CHEMBL375457 cxcr3_human Human No 6.8 IC50 = 146 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
509 14 0 5 6.6 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL583761 cxcr3_human Human No 6.8 IC50 = 146 Funct
Displacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assay
443 4 2 2 3.4 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5C
CHEMBL3697120 cxcr3_human Human No 6.8 IC50 = 146 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
521 11 1 6 2.0 CC1=CC=C(C=C1)C(C)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL3700579 cxcr3_human Human No 6.8 IC50 = 146 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
578 12 1 7 2.2 CC(C1=CC2=C(CCC2)C=C1)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CN(C5=O)C)OC
CHEMBL375457 cxcr3_human Human No 6.8 IC50 = 146 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
509 14 0 5 6.6 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL583761 cxcr3_human Human No 6.8 IC50 = 146 Funct
Displacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assay
443 4 2 2 3.4 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5C
CHEMBL1082660 cxcr3_human Human No 5.8 IC50 = 1460 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
470 8 1 7 3.9 COC1=CC=CC(=C1)CN(CC2=CC=C(C=C2)C3=NNN=N3)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1082660 cxcr3_human Human No 5.8 IC50 = 1460 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
470 8 1 7 3.9 COC1=CC=CC(=C1)CN(CC2=CC=C(C=C2)C3=NNN=N3)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL3700586 cxcr3_human Human No 6.8 IC50 = 149 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
549 11 1 7 1.6 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL578196 cxcr3_human Human No 6.8 IC50 = 149 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
684 9 0 14 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)C(F)(F)F)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL3700586 cxcr3_human Human No 6.8 IC50 = 149 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
549 11 1 7 1.6 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C4CC(C4)C(=O)O
CHEMBL578196 cxcr3_human Human No 6.8 IC50 = 149 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
684 9 0 14 4.6 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)C(F)(F)F)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1077831 cxcr3_human Human No 7.8 IC50 = 15 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL397983 cxcr3_human Human Yes 7.8 IC50 = 15 Funct
Antagonist activity at CXCR3 assessed as ITAC-mediated cell migrationAntagonist activity at CXCR3 assessed as ITAC-mediated cell migration
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL3697140 cxcr3_human Human No 7.8 IC50 = 15 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL257038 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL256457 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
545 8 1 3 6.4 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)C4=CC5=CC=CC=C5C=C4
CHEMBL272522 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL1939554 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
642 7 0 11 4.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL584518 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
588 9 0 10 4.1 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL397983 cxcr3_human Human Yes 7.8 IC50 = 15 Funct
Inhibition of ITAC-induced CXCR3 mediated cell migrationInhibition of ITAC-induced CXCR3 mediated cell migration
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL1077831 cxcr3_human Human No 7.8 IC50 = 15 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
689 11 0 14 5.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)OCC(F)(F)F)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL397983 cxcr3_human Human Yes 7.8 IC50 = 15 Funct
Antagonist activity at CXCR3 assessed as ITAC-mediated cell migrationAntagonist activity at CXCR3 assessed as ITAC-mediated cell migration
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL3697140 cxcr3_human Human No 7.8 IC50 = 15 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL257038 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL256457 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
545 8 1 3 6.4 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)C4=CC5=CC=CC=C5C=C4
CHEMBL272522 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL1939554 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
642 7 0 11 4.0 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)C#N)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL584518 cxcr3_human Human No 7.8 IC50 = 15 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC
588 9 0 10 4.1 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL397983 cxcr3_human Human Yes 7.8 IC50 = 15 Funct
Inhibition of ITAC-induced CXCR3 mediated cell migrationInhibition of ITAC-induced CXCR3 mediated cell migration
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL495752 cxcr3_human Human No 6.8 IC50 = 150 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
441 4 0 2 5.0 C1CC(CN(C1)C=O)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL3697066 cxcr3_human Human No 6.8 IC50 = 150 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
553 10 1 6 2.3 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL272558 cxcr3_mouse Mouse No 6.8 IC50 = 150 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
525 9 1 4 5.2 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)C4=CC=CC=C4OC
CHEMBL495752 cxcr3_human Human No 6.8 IC50 = 150 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
441 4 0 2 5.0 C1CC(CN(C1)C=O)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL3697066 cxcr3_human Human No 6.8 IC50 = 150 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
553 10 1 6 2.3 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL272558 cxcr3_mouse Mouse No 6.8 IC50 = 150 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
525 9 1 4 5.2 CN(CCCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)C4=CC=CC=C4OC
CHEMBL270166 cxcr3_mouse Mouse No 5.8 IC50 = 1500 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
495 8 1 3 4.8 CN(CCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)CC4=CC=CC=C4
CHEMBL270166 cxcr3_mouse Mouse No 5.8 IC50 = 1500 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
495 8 1 3 4.8 CN(CCN1C2=C(C=CC=C2Cl)N(C1=N)CC(=O)C3=CC=C(C=C3)Cl)C(=O)CC4=CC=CC=C4
CHEMBL196248 cxcr3_human Human No 4.8 IC50 = 15000 Funct
Inhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligandInhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligand
491 14 0 4 6.5 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3
CHEMBL196248 cxcr3_human Human No 4.8 IC50 = 15000 Funct
Inhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligandInhibitory concentration against CX3C chemokine receptor 3 expressed in human HEK293 cells using [125I]CXCL10 as radioligand
491 14 0 4 6.5 CCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3
CHEMBL3697156 cxcr3_human Human No 6.8 IC50 = 152 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
550 11 1 8 0.6 CC(C1=CC2=C(C=C1)OCC2)N(CC3=CC(=C(C=C3)OCCN4C(=O)C=CN(C4=O)C)OC)C5CC(C5)C(=O)O
CHEMBL3697157 cxcr3_human Human No 6.8 IC50 = 152 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
550 11 1 8 0.6 CC(C1=CC2=C(C=C1)OCC2)N(CC3=CC(=C(C=C3)OCCN4C(=O)C=CN(C4=O)C)OC)C5CC(C5)C(=O)O
CHEMBL3697110 cxcr3_human Human No 6.8 IC50 = 154 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
545 11 1 7 2.0 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)F
CHEMBL3697138 cxcr3_human Human No 6.8 IC50 = 154 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697116 cxcr3_human Human No 6.8 IC50 = 154 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
527 11 1 6 1.9 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC=C(C=C3)OCCN4C(=O)CCC4=O
CHEMBL231587 cxcr3_human Human No 6.8 IC50 = 154 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
537 16 0 5 7.7 CCCCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL3697110 cxcr3_human Human No 6.8 IC50 = 154 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
545 11 1 7 2.0 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)F
CHEMBL3697138 cxcr3_human Human No 6.8 IC50 = 154 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697116 cxcr3_human Human No 6.8 IC50 = 154 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
527 11 1 6 1.9 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC=C(C=C3)OCCN4C(=O)CCC4=O
CHEMBL231587 cxcr3_human Human No 6.8 IC50 = 154 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
537 16 0 5 7.7 CCCCCCCCCCCC(=O)N(CCN(C)C)C(C)C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F
CHEMBL3697134 cxcr3_human Human No 6.8 IC50 = 155 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
587 11 1 8 2.0 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=CC(=C(C=C34)F)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697134 cxcr3_human Human No 6.8 IC50 = 155 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
587 11 1 8 2.0 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=CC(=C(C=C34)F)Cl)OCCN5C(=O)CCC5=O
CHEMBL496570 cxcr3_human Human No 5.8 IC50 = 1550 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
471 5 1 4 3.8 COC1=CC=CC(=C1)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br
CHEMBL496570 cxcr3_human Human No 5.8 IC50 = 1550 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
471 5 1 4 3.8 COC1=CC=CC(=C1)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br
CHEMBL230344 cxcr3_human Human No 6.8 IC50 = 156 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
557 9 0 9 5.3 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CCN(C)C)C(=O)CC4=CC=C(C=C4)OC(F)(F)F
CHEMBL230344 cxcr3_human Human No 6.8 IC50 = 156 Funct
Displacement of [125I ]IP10 from CXCR3 receptor expressed in PBMCDisplacement of [125I ]IP10 from CXCR3 receptor expressed in PBMC
557 9 0 9 5.3 CC(C1=NC2=CC=CC=C2C(=O)N1C3=CC=C(C=C3)F)N(CCN(C)C)C(=O)CC4=CC=C(C=C4)OC(F)(F)F
CHEMBL1082360 cxcr3_human Human No 6.8 IC50 = 157 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
476 7 1 8 4.1 C1=CC=C(C(=C1)CN(CC2=CC(=C(C=C2)C3=NNN=N3)F)S(=O)(=O)C4=CC=C(C=C4)Cl)F
CHEMBL3697088 cxcr3_human Human No 6.8 IC50 = 157 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
570 12 1 6 2.7 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)CCCN4C(=O)CN(C4=O)C)OC
CHEMBL1082360 cxcr3_human Human No 6.8 IC50 = 157 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
476 7 1 8 4.1 C1=CC=C(C(=C1)CN(CC2=CC(=C(C=C2)C3=NNN=N3)F)S(=O)(=O)C4=CC=C(C=C4)Cl)F
CHEMBL3697088 cxcr3_human Human No 6.8 IC50 = 157 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
570 12 1 6 2.7 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)CCCN4C(=O)CN(C4=O)C)OC
CHEMBL1085508 cxcr3_human Human No 6.8 IC50 = 158 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
454 8 1 9 2.3 COC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC(=C(C=C2)C3=NNN=N3)F)CC4=CC=CC=N4
CHEMBL1085508 cxcr3_human Human No 6.8 IC50 = 158 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
454 8 1 9 2.3 COC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC(=C(C=C2)C3=NNN=N3)F)CC4=CC=CC=N4
CHEMBL479426 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
463 4 0 10 2.8 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=C(C=C(C=N4)C(F)(F)F)F)C
CHEMBL465283 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
460 4 0 9 3.1 CC1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL459950 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
448 4 1 9 3.0 CC1(C2CCC1(C(C2)O)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL481197 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
462 4 1 9 3.4 CC1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL464064 cxcr3_mouse Mouse No 6.8 IC50 = 158.5 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
480 4 1 10 3.5 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL479426 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
463 4 0 10 2.8 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=C(C=C(C=N4)C(F)(F)F)F)C
CHEMBL465283 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
460 4 0 9 3.1 CC1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4=O
CHEMBL459950 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
448 4 1 9 3.0 CC1(C2CCC1(C(C2)O)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL481197 cxcr3_human Human No 6.8 IC50 = 158.5 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
462 4 1 9 3.4 CC1CN(CCN1C2=NC=C(C=C2)C(F)(F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL464064 cxcr3_mouse Mouse No 6.8 IC50 = 158.5 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
480 4 1 10 3.5 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL498620 cxcr3_human Human No 5.8 IC50 = 1580 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
427 4 1 2 4.4 C1CC(C(=O)NC1)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL498620 cxcr3_human Human No 5.8 IC50 = 1580 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
427 4 1 2 4.4 C1CC(C(=O)NC1)(C2CCN(CC2)CC3=CC=C(C=C3)Br)C4=CC=CC=C4
CHEMBL459742 cxcr3_human Human No 5.8 IC50 = 1584.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
446 4 0 9 2.7 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL516872 cxcr3_human Human No 5.8 IC50 = 1584.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
456 4 0 6 2.5 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)Br)C
CHEMBL464065 cxcr3_mouse Mouse No 5.8 IC50 = 1584.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
480 4 1 10 3.5 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL464244 cxcr3_mouse Mouse No 5.8 IC50 = 1584.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
522 4 0 11 3.6 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC45OCCO5
CHEMBL459742 cxcr3_human Human No 5.8 IC50 = 1584.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
446 4 0 9 2.7 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL516872 cxcr3_human Human No 5.8 IC50 = 1584.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
456 4 0 6 2.5 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=NC=C(C=C4)Br)C
CHEMBL464065 cxcr3_mouse Mouse No 5.8 IC50 = 1584.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
480 4 1 10 3.5 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC4O
CHEMBL464244 cxcr3_mouse Mouse No 5.8 IC50 = 1584.9 Funct
Antagonist activity at mouse recombinant CXCR3 expressed in human U2OS cellsAntagonist activity at mouse recombinant CXCR3 expressed in human U2OS cells
522 4 0 11 3.6 CC1CN(CCN1C2=C(C=C(C=N2)C(F)(F)F)F)S(=O)(=O)CC34CCC(C3(C)C)CC45OCCO5
CHEMBL517024 cxcr3_human Human No 4.8 IC50 = 15848.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
428 4 0 6 3.0 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=CC5=CC=CC=C5C=N4)C
CHEMBL480601 cxcr3_human Human No 4.8 IC50 = 15848.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
460 5 1 9 3.3 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)NC3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL517024 cxcr3_human Human No 4.8 IC50 = 15848.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
428 4 0 6 3.0 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)N3CCN(CC3)C4=CC5=CC=CC=C5C=N4)C
CHEMBL480601 cxcr3_human Human No 4.8 IC50 = 15848.9 Funct
Antagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assayAntagonist activity at human recombinant CXCR3 receptor expressed in CHO-K1 cells assessed as human IP10-induced calcium flux by FLIPR assay
460 5 1 9 3.3 CC1(C2CCC1(C(=O)C2)CS(=O)(=O)NC3CCN(CC3)C4=NC=C(C=C4)C(F)(F)F)C
CHEMBL1681850 cxcr3_human Human No 7.8 IC50 = 16 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
621 7 1 5 6.9 CC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NCC5=CC(=C(C=C5)Cl)Cl)Cl
CHEMBL1809008 cxcr3_human Human No 7.8 IC50 = 16 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 2 3 2.0 C1COCCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809015 cxcr3_mouse Mouse No 7.8 IC50 = 16 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
445 2 2 3 2.9 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6F
CHEMBL1809029 cxcr3_mouse Mouse No 7.8 IC50 = 16 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
447 2 2 2 3.6 C1CCCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL403290 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL570858 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)C(F)(F)F
CHEMBL570665 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL437598 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
605 11 0 9 4.9 CCC1=C(N=C(N1C2=CC=C(C=C2)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4CC4
CHEMBL1809041 cxcr3_rat Rat No 7.8 IC50 = 16 Funct
Ex vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometryEx vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometry
538 5 1 3 3.6 C1CCN(CC1)CCN2C=C3CC4C(=CC(CN4C(=O)NC5=CC=CC=C5)C(=O)N6CCCC6)C7=C3C2=CC=C7
CHEMBL1681850 cxcr3_human Human No 7.8 IC50 = 16 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
621 7 1 5 6.9 CC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=C(C=C(C=N4)C(=O)NCC5=CC(=C(C=C5)Cl)Cl)Cl
CHEMBL1809008 cxcr3_human Human No 7.8 IC50 = 16 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 2 3 2.0 C1COCCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809015 cxcr3_mouse Mouse No 7.8 IC50 = 16 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
445 2 2 3 2.9 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6F
CHEMBL1809029 cxcr3_mouse Mouse No 7.8 IC50 = 16 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
447 2 2 2 3.6 C1CCCC(CC1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL403290 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from human CXCR3 expressed in CHO cell membrane
572 6 1 4 5.9 C1CC(CN(C1)C(=O)C2=CC=CC3=C2N=CC=C3)CN4C5=C(C=CC=C5Cl)N(C4=N)CC(=O)C6=CC=C(C=C6)Cl
CHEMBL570858 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
636 8 0 9 5.0 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC=C(C=C6)C(F)(F)F
CHEMBL570665 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL437598 cxcr3_human Human No 7.8 IC50 = 16 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
605 11 0 9 4.9 CCC1=C(N=C(N1C2=CC=C(C=C2)C#N)C(C)N(CCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4CC4
CHEMBL1809041 cxcr3_rat Rat No 7.8 IC50 = 16 Funct
Ex vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometryEx vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometry
538 5 1 3 3.6 C1CCN(CC1)CCN2C=C3CC4C(=CC(CN4C(=O)NC5=CC=CC=C5)C(=O)N6CCCC6)C7=C3C2=CC=C7
CHEMBL3697082 cxcr3_human Human No 6.8 IC50 = 160 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.5 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)CCCN5C(=O)CCC5=O
CHEMBL3697152 cxcr3_human Human No 6.8 IC50 = 160 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
572 13 1 7 2.3 CCC(C1=CC=C(C=C1)Cl)N(CC2C(C2(C)C)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)OC
CHEMBL1809027 cxcr3_human Human No 6.8 IC50 = 160 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
419 2 2 2 2.5 C1CCC(C1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL3697082 cxcr3_human Human No 6.8 IC50 = 160 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.5 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)CCCN5C(=O)CCC5=O
CHEMBL3697152 cxcr3_human Human No 6.8 IC50 = 160 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
572 13 1 7 2.3 CCC(C1=CC=C(C=C1)Cl)N(CC2C(C2(C)C)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)OC
CHEMBL1809027 cxcr3_human Human No 6.8 IC50 = 160 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
419 2 2 2 2.5 C1CCC(C1)NC(=O)N2CC(C=C3C2CC4=CNC5=CC=CC3=C45)C(=O)N6CCCC6
CHEMBL256660 cxcr3_human Human No 4.8 IC50 = 16000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
300 3 1 2 3.1 CN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC(=CC=C3)Cl
CHEMBL256660 cxcr3_human Human No 4.8 IC50 = 16000 Funct
Displacement of [125]CXCL10 from human CXCR3 expressed in CHO cellsDisplacement of [125]CXCL10 from human CXCR3 expressed in CHO cells
300 3 1 2 3.1 CN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC(=CC=C3)Cl
CHEMBL1077829 cxcr3_human Human No 6.8 IC50 = 162 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
599 8 0 10 4.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCOCC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL1077829 cxcr3_human Human No 6.8 IC50 = 162 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
599 8 0 10 4.9 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(C4CCOCC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL3697075 cxcr3_human Human No 6.8 IC50 = 163 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
579 12 1 8 1.6 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCCC5=O)OC
CHEMBL3697075 cxcr3_human Human No 6.8 IC50 = 163 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
579 12 1 8 1.6 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCCC5=O)OC
CHEMBL3700568 cxcr3_human Human No 5.8 IC50 = 1640 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
511 9 1 6 1.4 CC1=C(C=CC(=C1)CN(C2CCC3=C2C=CC(=C3)Cl)C4CC(C4)C(=O)O)OCCN5C(=O)CCC5=O
CHEMBL3700568 cxcr3_human Human No 5.8 IC50 = 1640 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
511 9 1 6 1.4 CC1=C(C=CC(=C1)CN(C2CCC3=C2C=CC(=C3)Cl)C4CC(C4)C(=O)O)OCCN5C(=O)CCC5=O
CHEMBL3700583 cxcr3_human Human No 6.8 IC50 = 165 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
585 11 1 7 2.8 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4F)Cl)OCCN5C(=O)CCC5=O
CHEMBL3700583 cxcr3_human Human No 6.8 IC50 = 165 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
585 11 1 7 2.8 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4F)Cl)OCCN5C(=O)CCC5=O
CHEMBL269981 cxcr3_human Human No 5.8 IC50 = 1659 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
578 13 0 8 3.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3N=C(N=N3)C4CC4)C5=CC=CC=C5
CHEMBL269981 cxcr3_human Human No 5.8 IC50 = 1659 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
578 13 0 8 3.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3N=C(N=N3)C4CC4)C5=CC=CC=C5
CHEMBL3697047 cxcr3_human Human No 5.8 IC50 = 1660 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697050 cxcr3_human Human No 5.8 IC50 = 1660 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697047 cxcr3_human Human No 5.8 IC50 = 1660 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697050 cxcr3_human Human No 5.8 IC50 = 1660 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697047 cxcr3_human Human No 5.8 IC50 = 1660 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697050 cxcr3_human Human No 5.8 IC50 = 1660 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
569 11 1 7 1.9 COC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3700578 cxcr3_human Human No 6.8 IC50 = 167 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
563 12 1 7 2.1 CC(C1=CC2=C(CCC2)C=C1)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL3700578 cxcr3_human Human No 6.8 IC50 = 167 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
563 12 1 7 2.1 CC(C1=CC2=C(CCC2)C=C1)N(CC3CCC(CC3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL3697095 cxcr3_human Human No 6.8 IC50 = 169 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
568 11 1 6 2.5 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC=C(C=C3)Cl)OCCN4C(=O)C=CN(C4=O)C
CHEMBL3697095 cxcr3_human Human No 6.8 IC50 = 169 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
568 11 1 6 2.5 CC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C(C)C3=CC=C(C=C3)Cl)OCCN4C(=O)C=CN(C4=O)C
CHEMBL1077817 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
655 9 0 11 6.5 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
CHEMBL1681833 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
511 5 1 5 4.8 CC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)Cl)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL570665 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL399285 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
615 9 0 10 3.5 CCS(=O)(=O)CCN(C(C)C1=C(C(=O)N2C=CC=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1939562 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
635 7 0 11 4.4 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)F)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL399285 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
615 9 0 10 3.5 CCS(=O)(=O)CCN(C(C)C1=C(C(=O)N2C=CC=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL577973 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1809002 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
425 2 2 2 2.6 C1C=CCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1077817 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasmaAntagonist activity against human CXCR3 expressed in human PBMC assessed as inhibition of cell migration in response to ITAC in plasma
655 9 0 11 6.5 CCOC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
CHEMBL1681833 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
511 5 1 5 4.8 CC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)Cl)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL570665 cxcr3_human Human No 7.8 IC50 = 17 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
628 10 0 10 4.7 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)C(=O)CC5=CC(=C(C=C5)C(F)(F)F)F
CHEMBL399285 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
615 9 0 10 3.5 CCS(=O)(=O)CCN(C(C)C1=C(C(=O)N2C=CC=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1939562 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]-IP-10 from CXCR3 in presence of 100% human serumDisplacement of [125I]-IP-10 from CXCR3 in presence of 100% human serum
635 7 0 11 4.4 CC(C1=NC2=C(C=CC=N2)C(=O)N1C3=CC=C(C=C3)F)N(CC4CCS(=O)(=O)CC4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
CHEMBL399285 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasmaDisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in EDTA-anti-coagulated human plasma
615 9 0 10 3.5 CCS(=O)(=O)CCN(C(C)C1=C(C(=O)N2C=CC=CC2=N1)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL577973 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasmaDisplacement of [125I]IP10 from CXCR3 receptor expressed in PBMC in presence of human plasma
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1809002 cxcr3_human Human No 7.8 IC50 = 17 Funct
Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay
425 2 2 2 2.6 C1C=CCN1C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL496571 cxcr3_human Human No 6.8 IC50 = 170 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
551 6 2 7 0.2 COC1=C(C=C(C=C1)S(=O)(=O)O)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br
CHEMBL1809036 cxcr3_human Human No 6.8 IC50 = 170 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
426 3 1 2 3.0 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)CC6=CC=CC=C6
CHEMBL3697166 cxcr3_human Human No 6.8 IC50 = 170 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
499 10 1 6 1.3 CC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC=C(C=C3)Cl)OCCN4C(=O)CCC4=O
CHEMBL370591 cxcr3_human Human No 6.8 IC50 = 170 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
613 9 3 5 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)OC
CHEMBL496571 cxcr3_human Human No 6.8 IC50 = 170 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
551 6 2 7 0.2 COC1=C(C=C(C=C1)S(=O)(=O)O)C2(CCC(=O)NC2=O)C3CCN(CC3)CC4=CC=C(C=C4)Br
CHEMBL1809036 cxcr3_human Human No 6.8 IC50 = 170 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
426 3 1 2 3.0 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)CC6=CC=CC=C6
CHEMBL3697166 cxcr3_human Human No 6.8 IC50 = 170 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
499 10 1 6 1.3 CC1=C(C=CC(=C1)CN(C2CC(C2)C(=O)O)C(C)C3=CC=C(C=C3)Cl)OCCN4C(=O)CCC4=O
CHEMBL370591 cxcr3_human Human No 6.8 IC50 = 170 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
613 9 3 5 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=C(C=C(C=C3)Cl)Cl)NC(=O)C4=CC(=CC=C4)OC
CHEMBL1809004 cxcr3_mouse Mouse No 5.8 IC50 = 1730 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
442 2 3 3 1.7 C1CN(CCN1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809004 cxcr3_mouse Mouse No 5.8 IC50 = 1730 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
442 2 3 3 1.7 C1CN(CCN1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697108 cxcr3_human Human No 6.8 IC50 = 176 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.7 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697108 cxcr3_human Human No 6.8 IC50 = 176 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
567 11 1 6 2.7 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697108 cxcr3_human Human No 6.8 IC50 = 176 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
567 11 1 6 2.7 CCC1=C(C=CC(=C1)CN(CC2CCC(CC2)C(=O)O)C3CCC4=C3C=CC(=C4)Cl)OCCN5C(=O)CCC5=O
CHEMBL3697089 cxcr3_human Human No 6.8 IC50 = 177 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
584 11 1 7 2.1 CN1CC(=O)N(C1=O)CCOC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)OC
CHEMBL3697038 cxcr3_human Human No 6.8 IC50 = 177 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
593 14 0 8 4.2 CCOC(=O)C1CCC(CC1)CN(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C(C)C4=CC5=C(C=C4)OCC5
CHEMBL3697089 cxcr3_human Human No 6.8 IC50 = 177 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
584 11 1 7 2.1 CN1CC(=O)N(C1=O)CCOC2=C(C=C(C=C2)CN(CC3CCC(CC3)C(=O)O)C4CCC5=C4C=CC(=C5)Cl)OC
CHEMBL3697038 cxcr3_human Human No 6.8 IC50 = 177 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
593 14 0 8 4.2 CCOC(=O)C1CCC(CC1)CN(CC2=CC(=C(C=C2)OCCN3C(=O)CCC3=O)OC)C(C)C4=CC5=C(C=C4)OCC5
CHEMBL573728 cxcr3_human Human No 6.8 IC50 = 179 Funct
Displacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assay
435 4 2 2 4.0 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5CCCCC5
CHEMBL573728 cxcr3_human Human No 6.8 IC50 = 179 Funct
Displacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assayDisplacement of [125I]I-TAC from human CXCR3 expressed in CHO cells by scintillation proximity assay
435 4 2 2 4.0 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5CCCCC5
CHEMBL1681835 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
494 5 1 6 4.3 CC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL584554 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assay
429 4 2 2 3.8 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL584554 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
429 4 2 2 3.8 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL570919 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
646 10 0 12 4.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)OC)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL577973 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1921888 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
471 5 1 6 3.0 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C4=NC=C(N=C4C)C(=O)N
CHEMBL254709 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
587 9 0 9 4.5 CCS(=O)(=O)CCN(C(C)C1=NN2C=CC=CC2=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL257209 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
646 13 0 9 6.1 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=CC=C4
CHEMBL402989 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
627 11 0 11 4.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL1681835 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3Antagonist activity at human CXCR3
494 5 1 6 4.3 CC1CN(CCN1C2CCN(CC2)CC3=C(C=C(C=C3)Cl)F)C4=C(C=C(C=N4)C(=O)NC)Cl
CHEMBL584554 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in L1.2 cells assessed as inhibition of I-TAC-induced Ca2+ mobilization by FLIPR assay
429 4 2 2 3.8 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL584554 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
429 4 2 2 3.8 CCN(CC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL570919 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
646 10 0 12 4.0 CCS(=O)(=O)CCN(C(C)C1=NC2=C(C=CC(=N2)OC)C(=O)N1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL577973 cxcr3_human Human No 7.8 IC50 = 18 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
618 10 0 11 4.4 CCS(=O)(=O)CCN(C(C)C1=C(N2C=CN=C(C2=N1)OC)C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)C(F)(F)F)F
CHEMBL1921888 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cellsDisplacement of [125I]CXCL10 from human CXCR3 expressed in mouse BA/F3 cells
471 5 1 6 3.0 CCC1CN(CCN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C4=NC=C(N=C4C)C(=O)N
CHEMBL254709 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSADisplacement of [125I]IP-10 from CXCR3 receptor expressed in human PBMC in RPMI-1640 buffer supplemented with 0.5% BSA
587 9 0 9 4.5 CCS(=O)(=O)CCN(C(C)C1=NN2C=CC=CC2=C1C3=CC=C(C=C3)C#N)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL257209 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
646 13 0 9 6.1 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCCS(=O)(=O)CC)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=CC=C4
CHEMBL402989 cxcr3_human Human No 7.8 IC50 = 18 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
627 11 0 11 4.7 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL578192 cxcr3_human Human No 7.7 IC50 = 18.9 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL578192 cxcr3_human Human No 7.7 IC50 = 18.9 Funct
Antagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasmaAntagonistic activity to CXCR3 receptor expressed in PBMC assessed as inhibition of ITAC-mediated cell migration in presence of 100% human plasma
654 8 0 10 5.1 CC(C1=C(N2C=CN=C(C2=N1)C3CC3)C4=CC=C(C=C4)C#N)N(CC5CCS(=O)(=O)CC5)C(=O)CC6=CC(=C(C=C6)C(F)(F)F)F
CHEMBL496176 cxcr3_human Human No 6.8 IC50 = 180 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
467 5 0 3 5.1 C1CC(CN(C1)C2CC2=O)(C3CCN(CC3)CC4=CC=C(C=C4)Br)C5=CC=CC=C5
CHEMBL3697150 cxcr3_human Human No 6.8 IC50 = 180 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
523 12 1 8 0.2 CC(C1=CC2=C(C=C1)OCC2)N(CC3CC3C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL3697107 cxcr3_human Human No 6.8 IC50 = 180 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
570 12 1 6 2.9 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)C
CHEMBL496176 cxcr3_human Human No 6.8 IC50 = 180 Funct
Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challengeAntagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge
467 5 0 3 5.1 C1CC(CN(C1)C2CC2=O)(C3CCN(CC3)CC4=CC=C(C=C4)Br)C5=CC=CC=C5
CHEMBL3697150 cxcr3_human Human No 6.8 IC50 = 180 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
523 12 1 8 0.2 CC(C1=CC2=C(C=C1)OCC2)N(CC3CC3C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL3697107 cxcr3_human Human No 6.8 IC50 = 180 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
570 12 1 6 2.9 CCC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CN(C4=O)C)C
CHEMBL256891 cxcr3_mouse Mouse No 5.8 IC50 = 1800 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
503 10 1 3 5.3 CCC1=C2C(=CC=C1)N(C(=N)N2CCCN(C)C(=O)CC3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)Cl
CHEMBL256891 cxcr3_mouse Mouse No 5.8 IC50 = 1800 Funct
Displacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membraneDisplacement of [125I]-CXCL10 from mouse CXCR3 expressed in CHO cell membrane
503 10 1 3 5.3 CCC1=C2C(=CC=C1)N(C(=N)N2CCCN(C)C(=O)CC3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)Cl
CHEMBL3697137 cxcr3_human Human No 5.7 IC50 = 1810 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697137 cxcr3_human Human No 5.7 IC50 = 1810 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
543 12 1 7 1.5 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(C2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697114 cxcr3_human Human No 6.7 IC50 = 182 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
592 12 1 7 2.5 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697114 cxcr3_human Human No 6.7 IC50 = 182 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
592 12 1 7 2.5 CC(C1=CC(=C(C=C1)Cl)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL1086040 cxcr3_human Human No 6.7 IC50 = 183 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
483 7 0 4 5.9 C1=CC=NC(=C1)CN(CC2=CC=C(C=C2)C3=CC(=CC=C3)Cl)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1086040 cxcr3_human Human No 6.7 IC50 = 183 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrsAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of IP10-induced chemotaxis after 4 hrs
483 7 0 4 5.9 C1=CC=NC(=C1)CN(CC2=CC=C(C=C2)C3=CC(=CC=C3)Cl)S(=O)(=O)C4=CC=C(C=C4)Cl
CHEMBL1808997 cxcr3_human Human No 6.7 IC50 = 187 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
489 8 2 4 2.0 COCCN(CCOC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1808997 cxcr3_human Human No 6.7 IC50 = 187 Funct
Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
489 8 2 4 2.0 COCCN(CCOC)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C(=O)NC5=CC=CC=C5
CHEMBL1806523 cxcr3_rat Rat No 7.7 IC50 = 19 Funct
Antagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometryAntagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometry
427 2 2 2 2.8 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809014 cxcr3_mouse Mouse No 7.7 IC50 = 19 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 3 3 1.9 C1CN(CC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697042 cxcr3_human Human No 7.7 IC50 = 19 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
557 12 1 7 1.9 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697124 cxcr3_human Human No 7.7 IC50 = 19 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
573 12 1 7 2.4 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)SCCN4C(=O)CCC4=O)OC
CHEMBL3697042 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting methodDisplacement of [125I]-CXCL10 from human recombinant CXCR3 transfected in Flp-In-CHO cell membranes after 60 mins by gamma counting method
557 12 1 7 1.9 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL403194 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
645 10 0 12 4.9 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL402375 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
682 13 0 11 5.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3N=C(N=N3)C4=CC=C(C=C4)C(F)(F)F)C5=CC=CC=C5
CHEMBL403491 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
579 10 0 9 4.6 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C(C)C)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F
CHEMBL1806523 cxcr3_rat Rat No 7.7 IC50 = 19 Funct
Antagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometryAntagonist activity at CXCR3 in rat leukocytes assessed as inhibition of ITAC-induced cell migration by flow cytometry
427 2 2 2 2.8 C1CCN(C1)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL1809014 cxcr3_mouse Mouse No 7.7 IC50 = 19 Funct
Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assayAntagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay
443 2 3 3 1.9 C1CN(CC1O)C(=O)C2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C(=O)NC6=CC=CC=C6
CHEMBL3697042 cxcr3_human Human No 7.7 IC50 = 19 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
557 12 1 7 1.9 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)OC
CHEMBL3697124 cxcr3_human Human No 7.7 IC50 = 19 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
573 12 1 7 2.4 CC(C1=CC=C(C=C1)Cl)N(CC2CCC(CC2)C(=O)O)CC3=CC(=C(C=C3)SCCN4C(=O)CCC4=O)OC
CHEMBL403194 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMCDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC
645 10 0 12 4.9 CCS(=O)(=O)CCN(C(C)C1=NC(=C(N1C2=CC=C(C=C2)C#N)C(F)(F)F)C3CC3)C(=O)CC4=CC(=C(C=C4)F)C(F)(F)F
CHEMBL402375 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
682 13 0 11 5.7 CCOC1=CC=C(C=C1)N2C=C(N=C2C(C)N(CCS(=O)(=O)CC)C(=O)CN3N=C(N=N3)C4=CC=C(C=C4)C(F)(F)F)C5=CC=CC=C5
CHEMBL403491 cxcr3_human Human No 7.7 IC50 = 19 Funct
Displacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasmaDisplacement of [125I]IP10 from human recombinant CXCR3 receptor expressed in IL2-activated human PBMC in presence of plasma
579 10 0 9 4.6 CCS(=O)(=O)CCN(C(C)C1=NC(=CN1C2=CC=C(C=C2)C#N)C(C)C)C(=O)CC3=CC(=C(C=C3)F)C(F)(F)F
CHEMBL3697154 cxcr3_human Human No 6.7 IC50 = 190 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
541 12 1 6 2.5 CCC(C1=CC=C(C=C1)Cl)N(CC2C(C2(C)C)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL3697144 cxcr3_human Human No 6.7 IC50 = 190 Funct
Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.Competition Radioligand Binding Assay: Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL202289 cxcr3_human Human No 6.7 IC50 = 190 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
583 8 3 4 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=CC=CC=C3Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL3697154 cxcr3_human Human No 6.7 IC50 = 190 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
541 12 1 6 2.5 CCC(C1=CC=C(C=C1)Cl)N(CC2C(C2(C)C)C(=O)O)CC3=CC(=C(C=C3)OCCN4C(=O)CCC4=O)C
CHEMBL3697144 cxcr3_human Human No 6.7 IC50 = 190 Funct
BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.BindingDB_Patents: Competition Radioligand Binding Assay. Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabeled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved.
551 12 1 8 0.9 CC(C1=CC2=C(C=C1)OCC2)N(CC3CCC(C3)C(=O)O)CC4=CC(=C(C=C4)OCCN5C(=O)CCC5=O)OC
CHEMBL202289 cxcr3_human Human No 6.7 IC50 = 190 Funct
Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5Inhibition of CXCL11-stimulated calcium release in HEK293 cells expressing recombinant human CXCR3 and chimeric G protein Gqi5
583 8 3 4 5.2 CCNC(=O)N1CCCN(CC1)C2=C(C=C(C=C2)C(=O)NCCC3=CC=CC=C3Cl)NC(=O)C4=CC(=CC=C4)Cl
CHEMBL397983 cxcr3_mouse Mouse Yes 5.7 IC50 = 1900 Funct
Receptor occupancy of CXCR3 in mouse whole blood assessed as inhibition of ITAC binding by fluorescence quenching based FACS analysisReceptor occupancy of CXCR3 in mouse whole blood assessed as inhibition of ITAC binding by fluorescence quenching based FACS analysis
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL397983 cxcr3_mouse Mouse Yes 5.7 IC50 = 1900 Funct
Receptor occupancy of CXCR3 in mouse whole blood assessed as inhibition of ITAC binding by fluorescence quenching based FACS analysisReceptor occupancy of CXCR3 in mouse whole blood assessed as inhibition of ITAC binding by fluorescence quenching based FACS analysis
604 10 0 10 5.2 CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F
CHEMBL1085509 cxcr3_human Human Yes